Piet Ost

Piet Ost: Can Durvalumab and SBRT improve outcomes in Oligorecurrent Prostate Cancer?

Piet Ost, Radiation Oncologist at Iridium Network Antwerp, shared a post on X:

“POSTCARD trial by Dr Supiot: Can durvalumab and SBRT improve outcomes in oligorecurrent Prostate Cancer?

  • No PFS benefit at 2 years vs SBRT alone.
  • Deeper PSA responses in some patients.
  • CTC count <5 linked to better outcomes.”

Piet Ost: Can Durvalumab and SBRT improve outcomes in Oligorecurrent Prostate Cancer?

More posts featuring Piet Ost.

cancer Durvalumab ESTRO25 fight against cancer Global fight against cancer Iridium Network Antwerp Oligorecurrent Prostate Cancer OncoDaily Oncology Piet Ost POSTCARD trial prostate cancer SBRT